SiRNAs Containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) Nucleotides: in Vitro and in Vivo RNAi Activity and Inability of Mitochondrial Polymerases to Incorporate 2'-F-NMC NTPs
Overview
Authors
Affiliations
We recently reported the synthesis of 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides, which are based on a bicyclo[3.1.0]hexane scaffold. Here, we analyzed RNAi-mediated gene silencing activity in cell culture and demonstrated that a single incorporation of 2'-F-NMC within the guide or passenger strand of the tri-N-acetylgalactosamine-conjugated siRNA targeting mouse Ttr was generally well tolerated. Exceptions were incorporation of 2'-F-NMC into the guide strand at positions 1 and 2, which resulted in a loss of the in vitro activity. Activity at position 1 was recovered when the guide strand was modified with a 5' phosphate, suggesting that the 2'-F-NMC is a poor substrate for 5' kinases. In mice, the 2'-F-NMC-modified siRNAs had comparable RNAi potencies to the parent siRNA. 2'-F-NMC residues in the guide seed region position 7 and at positions 10, 11 and 12 were well tolerated. Surprisingly, when the 5'-phosphate mimic 5'-(E)-vinylphosphonate was attached to the 2'-F-NMC at the position 1 of the guide strand, activity was considerably reduced. The steric constraints of the bicyclic 2'-F-NMC may impair formation of hydrogen-bonding interactions between the vinylphosphonate and the MID domain of Ago2. Molecular modeling studies explain the position- and conformation-dependent RNAi-mediated gene silencing activity of 2'-F-NMC. Finally, the 5'-triphosphate of 2'-F-NMC is not a substrate for mitochondrial RNA and DNA polymerases, indicating that metabolites should not be toxic.
Engineering siRNA therapeutics: challenges and strategies.
Ali Zaidi S, Fatima F, Zaidi S, Zhou D, Deng W, Liu S J Nanobiotechnology. 2023; 21(1):381.
PMID: 37848888 PMC: 10583313. DOI: 10.1186/s12951-023-02147-z.
Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M, Manoharan M Nucleic Acids Res. 2023; 51(6):2529-2573.
PMID: 36881759 PMC: 10085713. DOI: 10.1093/nar/gkad067.
Guenther D, Mori S, Matsuda S, Gilbert J, Willoughby J, Hyde S J Am Chem Soc. 2022; 144(32):14517-14534.
PMID: 35921401 PMC: 9389587. DOI: 10.1021/jacs.2c01679.
Gangopadhyay S, Gore K RNA Biol. 2022; 19(1):452-467.
PMID: 35352626 PMC: 8973385. DOI: 10.1080/15476286.2022.2052641.
Innovative developments and emerging technologies in RNA therapeutics.
Halloy F, Biscans A, Bujold K, Debacker A, Hill A, Lacroix A RNA Biol. 2022; 19(1):313-332.
PMID: 35188077 PMC: 8865321. DOI: 10.1080/15476286.2022.2027150.